Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ENO1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ENO1 Recombinant Protein (Human, Mouse, Cyno) High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed for native post-translational modifications. |
View ENO1 Products |
| Gene Delivery | ENO1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to evaluate surface-bound enolase conformation. |
View ENO1 Products |
| Benchmark Ab | Anti-ENO1 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View ENO1 Products |
| Validator | ENO1 siRNA Set Target-specific knockdown pool for functional validation and specificity controls. |
View ENO1 Products |
| Related Target A | ENO2 (Enolase 2) Critical for selectivity counter-screening in collateral lethality strategies (ENO1-deleted cancers). |
View ENO2 Products |
| Related Target B | PLG (Plasminogen) Primary functional partner. Surface-bound ENO1 acts as a receptor for PLG to promote extracellular matrix degradation. |
View PLG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily (ENO2/ENO3) off-target screening | Homolog panel proteins strictly verified by mass spectrometry to ensure zero cross-contamination. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included for assay calibration. |
| False Positives | Validated siRNA transfection pools included for target-specific knockdown verification. |
Live ENO1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ENO1 therapeutics is intensifying, with major players shifting focus from traditional systemic metabolic inhibition to targeting surface-expressed ENO1. As first-generation therapies reach the clinic, the next wave of R&D is targeting surface-bound ENO1 with monoclonal antibodies, antibody-drug conjugates (ADCs), and CAR-T cell therapies to exploit its role as a plasminogen receptor in tumor metastasis.
Concurrently, "collateral lethality" (旁路致死) strategies are emerging in glioblastoma and other cancers harboring 1p36 locus deletions (which contain the ENO1 gene). In these indications, selective small-molecule inhibitors of ENO2 are deployed to selectively kill ENO1-deficient tumor cells while sparing normal tissue, necessitating highly specific ENO1/ENO2 counter-screening assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Academic institutions, Biotech startups | Pancreatic Cancer, NSCLC, Autoimmune Diseases | Plasminogen-binding blocking assays (Need high-purity ENO1 and PLG proteins) |
| CAR-T / Cell Therapy | Clinical-stage cell therapy developers | Solid Tumors, Multiple Myeloma | Surface-expression validation (Need Lentivirus for stable cell line construction) |
| Small Molecule (Collateral Lethality) | Oncology-focused biotechs | Glioblastoma (ENO1-deleted) | Selectivity assays (Need Mutant and WT recombinant ENO1 vs. ENO2 proteins) |